This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (84)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Study of the Mayo Clinic and the North Central Cancer Treatment Group

Robert W. Beart, Jr, MD; Charles G. Moertel, MD; Harry S. Wieand, PhD; John E. Leigh, MD; Harry E. Windschitl, MD; Jonathan A. van Heerden, MD; RobertJ. Fitzgibbons, Jr, MD; Bruce G. Wolff, MD

Arch Surg. 1990;125(7):897-901.

Abstract
• We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.

(Arch Surg. 1990;125:897-901)

Author Affiliations
From the Mayo Clinic, Scottsdale, Ariz (Dr Beart); Mayo Clinic, Rochester, Minn (Drs Moertel, Wieand, van Heerden, and Wolff), and St Cloud (Minn) Clinic of Internal Medicine, Ltd (Dr Windschitl); St Luke's Hospitals CCOP, Fargo, ND (Dr Leigh); and Creighton University, Omaha, Neb (Dr Fitzgibbons).

Footnotes
Accepted for publication January 30, 1990.

Read before the annual meeting of the Society of Surgical Oncology, San Francisco, Calif, May 21-24, 1989.

Reprint requests to 13400 E Shea Blvd, Scottsdale, AZ 85259 (Dr Beart).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adjuvant Treatment of Colorectal Cancer
Wolpin et al.
CA Cancer J Clin 2007;57:168-185.
ABSTRACT | FULL TEXT  

Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group
Figueredo et al.
JCO 2004;22:3395-3407.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson et al.
JCO 2004;22:3408-3419.
ABSTRACT | FULL TEXT  

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic et al.
NEJM 2003;349:247-257.
ABSTRACT | FULL TEXT  

Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer
Allegra et al.
JCO 2002;20:1735-1743.
ABSTRACT | FULL TEXT  

Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
Halling et al.
JNCI J Natl Cancer Inst 1999;91:1295-1303.
ABSTRACT | FULL TEXT  

Raltitrexed and the treatment of advanced colorectal cancer
Summerhayes
J Oncol Pharm Pract 1996;2:225-235.
ABSTRACT